血管内间充质基质/干细胞治疗产品多样化：是时候制定新的临床指南了。

Intravascular Mesenchymal Stromal/Stem Cell Therapy Product Diversification: Time for New Clinical Guidelines.

机构信息

Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin (FUB), Humboldt-Universität zu Berlin (HUB), and Berlin Institute of Health (BIH), Berlin, Germany; Berlin-Brandenburg School for Regenerative Therapies (BSRT), Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin (FUB), Humboldt-Universität zu Berlin (HUB), and Berlin Institute of Health (BIH), Berlin, Germany; Department of Nephrology and Internal Intensive Care Medicine, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin (FUB), Humboldt-Universität zu Berlin (HUB), and Berlin Institute of Health (BIH), Berlin, Germany.

Roy J. Carver Department of Biomedical Engineering, University of Iowa, Iowa City, IA, USA; Fraternal Order of Eagles Diabetes Research Center, Pappajohn Biomedical Institute, University of Iowa, Iowa City, IA, USA.

出版信息

Trends Mol Med. 2019 Feb;25(2):149-163. doi: 10.1016/j.molmed.2018.12.006. Epub 2019 Jan 30.

DOI:10.1016/j.molmed.2018.12.006

PMID:30711482

Abstract

Intravascular infusion is the most popular route for therapeutic multipotent mesenchymal stromal/stem cell (MSC) delivery in hundreds of clinical trials. Meta-analysis has demonstrated that bone marrow MSC infusion is safe. It is not clear if this also applies to diverse new cell products derived from other sources, such as adipose and perinatal tissues. Different MSC products display varying levels of highly procoagulant tissue factor (TF) and may adversely trigger the instant blood-mediated inflammatory reaction (IBMIR). Suitable strategies for assessing and controlling hemocompatibility and optimized cell delivery are crucial for the development of safer and more effective MSC therapies.

摘要

血管内输注是数百项治疗性多能间充质基质/干细胞（MSC）临床试验中最常用的给药途径。荟萃分析表明骨髓 MSC 输注是安全的。但目前尚不清楚这是否也适用于源自其他来源（如脂肪和围产期组织）的各种新型细胞产品。不同的 MSC 产品显示出不同水平的高度促凝组织因子（TF），并可能不利地引发即时血介导的炎症反应（IBMIR）。用于评估和控制血液相容性和优化细胞递送的合适策略对于开发更安全、更有效的 MSC 疗法至关重要。